Roche‘s (OTC:RHHBY) Genentech reported this week that the company launched three Phase III trials evaluating the Port drug-delivery implant in patients with wet age-related macular degeneration and diabetic macular edema.
The device is a refillable eye implant designed to continuously release drugs over a period of several months.
Get the full story at our sister site, Drug Delivery Business News.
The post Genentech kicks off Phase III trials for eye implant appeared first on MassDevice.